Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection

Journal of Hospital Medicine

Volumn 9, Issue 4, 2014, Pages 232-238

  Macvane, Shawn H ^a   Tuttle, Lindsay O ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ECONOMIC ASPECT; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA; FEMALE; HEALTH CARE COST; HOSPITAL READMISSION; HUMAN; KLEBSIELLA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REIMBURSEMENT; URINARY TRACT INFECTION; VERY ELDERLY; ANTIBIOTIC RESISTANCE; COMORBIDITY; COST; DRUG EFFECTS; ESCHERICHIA COLI; ISOLATION AND PURIFICATION; RETROSPECTIVE STUDY; RISK FACTOR; URINARY TRACT INFECTIONS;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; COMORBIDITY; COSTS AND COST ANALYSIS; ESCHERICHIA COLI; FEMALE; HUMANS; KLEBSIELLA; LENGTH OF STAY; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; URINARY TRACT INFECTIONS;

EID: 84898602351     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.2157     Document Type: Article

References (42)

1. Litwin MS, Saigal CS, Yano EM, et al. Urologic diseases in America project: analytical methods and principal findings. J Urol. 2005;173(3):933-937.
2. Nicolle LE. Urinary tract pathogens in complicated infection and in elderly individuals. J Infect Dis. 2001;183(suppl 1):S5-S8.
3. Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis. 2011;70(4):507-511.
4. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-686.
5. Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23(4):320-326.
6. Livermore DM. Defining an extended-spectrum beta-lactamase. Clin Microbiol Infect. 2008;14(suppl 5):3-10.
7. Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother. 2007;60(5):1018-1029.
8. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis. 2001;32(suppl 2):S94-S103.
9. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004. Am J Infect Control. 2004;32(8):470-485.
10. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum β-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis. 2005;53(4):257-264.
11. Pitout JDD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum b-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005;56(1):52-59.
12. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum B-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis. 2000;30(4):473-478.
13. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis. 2001;33(8):1288-1294.
14. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2005;49(5):2137-2139.
15. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000;31(suppl 4):S131-S138.
16. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(suppl 2):S82-S89.
17. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001:32(8):1162-1171.
18. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51(6):1987-1994.
19. Schwaber M, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60(5):913-920.
20. Tumbarello M, Spanu T, Di Bidino R, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-β-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54(10):4085-4091.
21. Rottier WC, Ammerlann HSM, Bonten MJM. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012;67(6):1311-1320.
22. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 21st informational supplement. M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
24. Kang C, Kim S, Park W, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 2005;49(2):760-766.
25. Kim BN, Woo JH, Kim MN, Ruy J, Kim YS. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect. 2002;52(2):99-106.
26. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006;27(11):1226-1232.
27. Calbo E, Romani V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum-β-lactamases. J Antimicrob Chemother. 2006:57(4):780-783.
28. Rodriguez-Bano J, Alcala JC, Cisneros JM, et al. Community infections caused extended-spectrum-β-lactamase-producing Escherichia coli. Arch Intern Med. 2008;168(17):1897-1902.
29. Lee DS, Lee CB, Lee SJ. Prevalence and risk factors for extended spectrum-β-lactamase-producing uropathogens in urinary tract infection. Korean J Urol. 2010;51(7):492-497.
30. Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum β-lactamase-producing gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39(4):333-340.
31. Tinelli M, Cataldo MA, Mantengoli E, et al. Epidemiology and genetic characteristics of extended-spectrum-β-lactamase-producing gram-negative bacteria causing urinary tract infections in long-term care facilities. J Antimicrob Chemother. 2012;67(12):2982-2987.
32. Briongos-Figuero LS, Gomez-Traveso T, Bachiller-Luque P, et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract. 2012;66(9):891-896.
33. Tumbarello M, Trecarichi EM, Bassetti M, et al. Identifying patients harboring extended-spectrum-β-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother. 2011;55(7):3485-3490.
34. Johnson SW, Anderson DJ, May DB, Drew RH. Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum-β-lactamase-producing Enterobacteriaceae on hospital admission. Infect Control Hosp Epidemiol. 2013;34(4):385-392.
35. Pullukcu H, Tasbakan M, Siphai OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Amtimicrob Agents. 2007;29(1):62-65.
36. Tasbakan MI, Pullukcu H, Sipahi OR, Yamazhan T, Ulusoy Nitrofurantoin in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infection. Int J Antimicrob Agents. 2012;40:554-556.
37. Rodriguez-Bano J, Navarro MD, Romero L, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microb. 2004;42(3):1089-1094.
38. Rodriguez-Bano J, Alcala JC, Cisneros JM, et al. Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Arch Intern Med. 2008:168(17):1897-1902.
39. Du B, Long Y, Liu H, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med. 2002;28(12):1718-1723.
40. Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis. 1996;174(3):529-536.
41. Cosgrove SE, Carmel Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003;36(11):1433-1437.
42. MacGowan AP. Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother. 2008;62(suppl 2):ii105-ii114.